Recombinant factor VIIa

BioDrugs

Volumn 12, Issue 1, 1999, Pages 71-77

  Dunn, Christopher J ^a   Spencer, Caroline M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ARTICLE; BLOOD CLOTTING; CLINICAL ARTICLE; DOSE RESPONSE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; EPISTAXIS; HEADACHE; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HUMAN; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; MEAN RESIDENCE TIME; PARTIAL THROMBOPLASTIN TIME; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PROTHROMBIN TIME;

EID: 0032766869     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-199912010-00008     Document Type: Article

References (23)

1. 1. Hampton KK, Preston FE. Bleeding disorders, thrombosis, and anticoagulation. BMJ 1997 Apr 5; 314: 1026-33
2. 2. Rice KM, Savidge GF. NovoSeven® (recombinant factor VIIa) in central nervous system bleeds. Haemostasis 1996 Jan; 26 Suppl. 1; 131-4
3. 3. Lusher J, Ingerslev J, Roberts H, et al. Clinical experience with recombinant factor VIIa. Blood Coagul Fibrinolysis 1998 Mar; 9: 119-28
4. 4. Hedner U. Recombinant activated factor VII as a universal haemostatic agent. Blood Coagul Fibrinolysis 1998 Mar; 9 Suppl. 1: 147-52
5. 5. ten Cate H, Bauer KA, Levi M, et al. The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor. J Clin Invest 1993 Sep; 92: 1207-12
6. 6. Rao LV, Rapaport SI. Factor VIIa-catalysed activation of factor X independent of tissue factor. Its possible significance for control of hemophilic blooding by infused factor VIIa. Blood 1990; 75: 1069-73
7. 7. Hoffman M, Monroe DM, Roberts HR. Human monocytes support factor X activation by factor VIIa, independent of tissue factor: implications for the therapeutic mechanism of high-dose factor VIIa in hemophilia. Blood 1994; 83: 38-42
8. 8. Monroe DM, Hoffman M, Oliver JA, et al. High dose factor VIIa activates factor X on activated platelets in the absence of tissue factor [abstract]. Thromb Haemost 1997 Jun; Suppl.: 168
9. 9. Macik BG, Lindley CM, Lusher J, et al. Safety and initial clinical efficacy of three dose levels of recombinant activated factor VII (rFVIIa): results of a phase I study. Blood Coagul Fibrinolysis 1993 Aug; 4: 521-7
10. 10. Shapiro AD, Gilchrist GS, Hoots WK, et al. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost 1998 Nov; 80: 773-8
11. 11. Lindley CM, Sawyer WT, Macik BG, et al. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther 1994 Jun; 55: 638-48
12. 12. Lusher JM, Roberts HR, Davignon G, et al. A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B. with and without inhibitors. rFVIIa Study Group, Haemophilia 1998; 4: 790-8
13. 13. Hay CR, Negrier C, Ludlam CA. The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multi centre study. Thromb Haemost 1997 Dec; 78: 1463-7
14. 14. Mølskov Bech R. Recombinant factor VIIa in joint and muscle bleeding episodes. Haemostasis 1996; 26 Suppl 1; 135-8
15. 15. Lusher JM. Recombinant factor VIIa (NovoSeven®) in the treatment of internal bleeding in patients with factor VIII and IX inhibitors. Haemostasis 1996 Jan; 26 Suppl. 1; 124-30
16. 16. Arkin S, Cooper HA, Hutter JJ, et al. Activated recombinant human coagulation factor VII therapy for intracranial hemorrhage in patients with hemophilia A or B with inhibitors. Haemostasis 1998; 28: 93-8
17. 17. Ingerslev J, Freidman D, Gastineau D, et al. Major surgery in haemophilic patients with inhibitors using recombinant factor VIIa. Haemostasis 1996 Jan; 26 Suppl. 1: 118-23
18. 18. Key NS, Aledort LM, Beardsley D, et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost 1998 Dec; 80: 912-8
19. 19. Laurian Y, Goudemand J, Négrier C, et al. Use of recombinant activated factor VII as first-line therapy for bleeding episodes in haemophiliacs with factor VIII or IX inhibitors (NOSEPAC study). Blood Coagul Fibrinolysis 1998 Mar; 9 Suppl. 1; S155-6
20. 20. Ingerslev J, Thykjaer H, Scheibel E. Approaches towards successful home treatment in patients with inhibitors. Eur J Haematol 1998; 61 Suppl. 63: 11-4
21. 21. Schulman S. Safety, efficacy and lessons from continuous infusion with rFVIIA. Haemophilia 1998 Jul; 4: 564-7
22. 22. Novo Nordisk Pharmaceuticals Limited. Novoseven. ABP1 Compendium of Data Sheets and Summaries of Product Characteristics 1998-1999. London: Datapharm Publications Ltd
23. 23. Nicolaisen EM. Antigenicity of activated recombinant factor VII followed through nine years of clinical experience. Blood Coagul Fibrinolysis 1998 Mar; 9 Suppl. 1; S119-23